
IRIX
IRIDEX Corp
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.590
Open
1.450
VWAP
1.48
Vol
379.81K
Mkt Cap
23.67M
Low
1.390
Amount
560.80K
EV/EBITDA(TTM)
--
Total Shares
16.25M
EV
26.07M
EV/OCF(TTM)
--
P/S(TTM)
0.48
IRIDEX Corporation is an ophthalmic medical technology company. It develops and commercializes products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its MicroPulse Technology and Endpoint Management Technology are used for the treatment of glaucoma and retina disorders. Its laser consoles product consists of Glaucoma, Medical Retina and Surgical Retina. Its glaucoma console line is the Cyclo G6 laser system with MicroPulse technology. Its surgical-retina product line includes its OcuLight TX and OcuLight SLx laser photocoagulation systems. Its medical-retina product line includes its portable IQ 532 and IQ 577 laser systems. Its laser probes products include Glaucoma and Surgical Retina. Probes used in its glaucoma product line include its patented single-use delivery devices-MicroPulse P3, G-Probe, and G-Probe Illuminate. Probes used in its surgical retina product line include its family of single-use EndoProbe handpieces.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
FY2024Q4
FY2024Q3
12.10M
+2.88%
--
--
12.80M
+2.75%
--
--
12.50M
-2.72%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for IRIDEX Corporation (IRIX) for FY2024, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 8.46%.
Revenue Estimates for FY2024
No Change

0.00%
In Past 3 Month
Stock Price
Go Up

+8.46%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for IRIDEX Corp (IRIX.O) is -4.89, compared to its 5-year average forward P/E of -8.08. For a more detailed relative valuation and DCF analysis to assess IRIDEX Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-8.08
Current PE
-4.89
Overvalued PE
-3.06
Undervalued PE
-13.09
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-7.07
Current EV/EBITDA
-11.06
Overvalued EV/EBITDA
-1.98
Undervalued EV/EBITDA
-12.17
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
0.95
Current PS
0.45
Overvalued PS
1.51
Undervalued PS
0.39
Financials
Annual
Quarterly
FY2025Q1
YoY :
+1.15%
11.90M
Total Revenue
FY2025Q1
YoY :
-133.25%
1.10M
Operating Profit
FY2025Q1
YoY :
-51.33%
-1.69M
Net Income after Tax
FY2025Q1
YoY :
-52.38%
-0.10
EPS - Diluted
FY2025Q1
-1.16M
Free Cash Flow
FY2025Q1
YoY :
+12.11%
42.49
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
-14.17
Net Margin - %
Trading Trends
Insider
Insiders areBuying! The selling amount has increased 125.71% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
25
74.2K
USD
Months
3-6
14
123.5K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
61.8K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areBuying! The selling amount has increased 125.71% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
25
74.2K
USD
Months
3-6
14
123.5K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
IRIX News & Events
Events Timeline
2025-06-24 (ET)
2025-06-24
07:03:27
Iridex announces first patient enrolled in investigator-led study of MicroPulse

2025-03-19 (ET)
2025-03-19
09:20:49
Iridex appoints Romeo Dizon as CFO

2025-03-19
09:19:59
Iridex announces closing of strategic investment in company

Sign Up For More Events
Sign Up For More Events
News
5.0
06-30NewsfilterVicarious Surgical Announces Election of New Directors
9.0
06-24NewsfilterIridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema
3.0
04-14NewsfilterIridex Announces Preliminary Operational and Financial Results for the First Quarter 2025
Sign Up For More News
People Also Watch

OXBR
Oxbridge Re Holdings Ltd
2.040
USD
-2.86%

GTIM
Good Times Restaurants Inc
1.495
USD
+1.70%

AXDX
Accelerate Diagnostics Inc
0
USD
-158.82%

OESX
Orion Energy Systems Inc
0.598
USD
+0.67%

WKSP
Worksport Ltd
3.760
USD
+2.17%

GDTC
CytoMed Therapeutics Ltd
1.866
USD
-1.79%

GLBS
Globus Maritime Ltd
1.110
USD
-0.89%

SVT
Servotronics Inc
0
USD
-0.11%

COOT
Australian Oilseeds Holdings Ltd
0.509
USD
+1.80%

EMKR
EMCORE Corp
0
USD
+0.81%
FAQ

What is IRIDEX Corp (IRIX) stock price today?
The current price of IRIX is 1.41 USD — it has increased 6.82 % in the last trading day.

What is IRIDEX Corp (IRIX)'s business?

What is the price predicton of IRIX Stock?

What is IRIDEX Corp (IRIX)'s revenue for the last quarter?

What is IRIDEX Corp (IRIX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for IRIDEX Corp (IRIX)'s fundamentals?

How many employees does IRIDEX Corp (IRIX). have?
